TriangleNCT03783442 · OUTCOME
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) and Physical Functioning Scales
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- LEAST_SQUARES_MEAN
- Unit
- score on a scale
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline, Cycle 6 (Week 15)
What was measured
The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
Analysis population: Participants in the ITT Analysis Set who completed the EORTC QLQ-C30 at Baseline and at least one post-baseline measurement.
Groups in this outcome
Tislelizumab + Chemotherapy
Participants received tislelizumab 200 mg administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.
Placebo + Chemotherapy
Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.
| Group | Source count |
|---|---|
| Tislelizumab + Chemotherapy | 310 |
| Placebo + Chemotherapy | 309 |
Reported measurements
Global Health Status/ QOL
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Tislelizumab + Chemotherapy | -0.3 | Not reported | -2.3 | 1.8 | Not reported |
| Placebo + Chemotherapy | -3.6 | Not reported | -5.8 | -1.4 | Not reported |
Physical Functioning
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Tislelizumab + Chemotherapy | -4.8 | Not reported | -6.6 | -3.0 | Not reported |
| Placebo + Chemotherapy | -7.3 | Not reported | -9.2 | -5.4 | Not reported |
Source statistical analyses
- ci Lower Limit
- 0.4
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 6.2
- estimate Comment
- Based on a mixed effect model analysis, with QLQ-C30 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
- group Description
- Analysis of Change from Baseline in Global Health Status/QoL at Cycle 6
- group Ids
- OG000
- OG001
- non Inferiority Type
- OTHER
- param Type
- LS Mean Difference
- param Value
- 3.3
- ci Lower Limit
- 0.0
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 5.1
- estimate Comment
- Based on a mixed effect model analysis, with QLQ-C30 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
- group Description
- Analysis of Change from Baseline in Physical Functioning at Cycle 6
- group Ids
- OG000
- OG001
- non Inferiority Type
- OTHER
- param Type
- LS Mean Difference
- param Value
- 2.6
Complete source fields
- analyses
- ci Lower Limit
- 0.4
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 6.2
- estimate Comment
- Based on a mixed effect model analysis, with QLQ-C30 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
- group Description
- Analysis of Change from Baseline in Global Health Status/QoL at Cycle 6
- group Ids
- OG000
- OG001
- non Inferiority Type
- OTHER
- param Type
- LS Mean Difference
- param Value
- 3.3
- ci Lower Limit
- 0.0
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 5.1
- estimate Comment
- Based on a mixed effect model analysis, with QLQ-C30 scores until cycle 18 as the response variable, and treatment by study visit interaction, Baseline mean score, and randomization stratification factors as covariates.
- group Description
- Analysis of Change from Baseline in Physical Functioning at Cycle 6
- group Ids
- OG000
- OG001
- non Inferiority Type
- OTHER
- param Type
- LS Mean Difference
- param Value
- 2.6
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- -2.3
- upper Limit
- 1.8
- value
- -0.3
- group Id
- OG001
- lower Limit
- -5.8
- upper Limit
- -1.4
- value
- -3.6
- title
- Global Health Status/ QOL
- categories
- measurements
- group Id
- OG000
- lower Limit
- -6.6
- upper Limit
- -3.0
- value
- -4.8
- group Id
- OG001
- lower Limit
- -9.2
- upper Limit
- -5.4
- value
- -7.3
- title
- Physical Functioning
- denoms
- counts
- group Id
- OG000
- value
- 310
- group Id
- OG001
- value
- 309
- units
- Participants
- description
- The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed to a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants received tislelizumab 200 mg administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.
- id
- OG000
- title
- Tislelizumab + Chemotherapy
- description
- Participants received placebo administered IV on Day 1 of each 3-week treatment cycle together with an investigator-chosen chemotherapy doublet until unacceptable toxicity, disease progression or withdrawal for other reasons.
- id
- OG001
- title
- Placebo + Chemotherapy
- param Type
- LEAST_SQUARES_MEAN
- population Description
- Participants in the ITT Analysis Set who completed the EORTC QLQ-C30 at Baseline and at least one post-baseline measurement.
- reporting Status
- POSTED
- time Frame
- Baseline, Cycle 6 (Week 15)
- title
- Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30) Global Health Status/Quality of Life (GHS/QoL) and Physical Functioning Scales
- type
- SECONDARY
- unit Of Measure
- score on a scale
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice